Recent Press Releases

MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Emergent BioSolutions Inc. (NYSE: EBS) today announced an agreement for the joint development and commercialization of ES414....

Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function Comparability to ERT Also Demonstrated in...

FDA approves new drug to treat a form of Gaucher disease

The U.S. Food and Drug Administration today approved Cerdelga (eliglustat) for the long-term treatment of adult patients with the Type 1 form of Gaucher disease, a rare genetic disorder. Gaucher...

FDA Approves Genzyme's Cerdelga™ (eliglustat) Capsules

Only First-Line Oral Therapy Approved for the Treatment of Adults with Gaucher Disease Type 1 CAMBRIDGE, Mass.—Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the...

Sanford-Burnham Appoints Perry Nisen as Chief Executive Officer

Dr. Nisen Will Lead the Implementation of Sanford-Burnham's New 10-Year Strategic Vision and Expand the Institute's Therapeutics Discovery Efforts LA JOLLA, CA, Aug 19, 2014 --...

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD

RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose...

Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors

REDWOOD CITY, Calif.--Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today...

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection) INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food...

Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company

Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company TEL AVIV, Israel, August 19, 2014 /PRNewswire via COMTEX/ -- TEL AVIV, Israel, August 19,...

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis Second...

Comprehend Raises $21 Million in Series B Funding

REDWOOD CITY, Calif.--Comprehend today announced it has secured $21 million in Series B financing to accelerate clinical development through its cloud-based business intelligence solutions, enabling...

Pfizer Announces Submission of Palbociclib New Drug Application to the FDA

Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval...

Novo Nordisk accepts fine for violating disclosure obligation in Denmark

Novo Nordisk accepts fine for violating disclosure obligation in Denmark Bagsværd, Denmark, 18 August 2014 – Novo Nordisk A/S has accepted a DKK 500,000 fine imposed by the Public...

EISAI SUBMITS MARKETING APPROVAL APPLICATIONS FOR ANTICANCER AGENT LENVATINIB SIMULTANEOUSLY IN EUROPE AND U.S.

EISAI SUBMITS MARKETING APPROVAL APPLICATIONS FOR ANTICANCER AGENT LENVATINIB SIMULTANEOUSLY IN EUROPE AND U.S. August 18, 2014 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,...

Biogen Idec's PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis

Biogen Idec's PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis CAMBRIDGE, Mass., Aug 15, 2014 (BUSINESS WIRE) -- Today Biogen Idec BIIB, +1.62%...

Avion Pharmaceuticals, LLC, signs Captisol® License Agreement with Ligand Pharmaceuticals to develop four new products

ATLANTA, Aug. 15, 2014 -- Avion Pharmaceuticals, LLC, announces the signing of a commercial license agreement withLigand Pharmaceuticals Incorporated (NASDAQ: LGND) for the development and...

The Lancet: Virus-like particle vaccine shows promise against chikungunya virus infection in first human trial

The first human trial of a new vaccine developed using non-infectious virus-like particles (VLP) appears likely to offer protection against chikungunya virus[1], a mosquito-borne infection, according...

Ex-Merck & Co., Inc. (MRK) Exec Appointed New President And CEO Of Medivir AB (MVRBF)

Today, Medivir AB (MVRBF) announced that its board of directors has appointed Niklas Prager to become the new CEO and president of the company beginning Sept. 1. Prager will bring years of experience...

Inotek Pharmaceuticals Corporation Brings In A New President And CEO

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on ophthalmology, today announced that David. P. Southwell has been named President...